Skip to main content
SpringerLink
Log in

Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Buffon A, Biasucci LM, Liuzzo G, et al.: Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5–12.

    Article  PubMed  Google Scholar 

  2. Libby P: Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006, 98:3Q–9Q.

    Article  PubMed  CAS  Google Scholar 

  3. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250–252.

    Article  PubMed  Google Scholar 

  4. Morrow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31:1460–1465.

    Article  PubMed  CAS  Google Scholar 

  5. Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 2006, 114:281–288.

    Article  PubMed  CAS  Google Scholar 

  6. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001, 2:108–115.

    Article  PubMed  CAS  Google Scholar 

  7. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al.: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858–864.

    Article  PubMed  CAS  Google Scholar 

  8. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991, 88:1121–1127.

    Article  PubMed  CAS  Google Scholar 

  9. Cushing SD, Berliner JA, Valente AJ, et al.: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990, 87:5134–5138.

    Article  PubMed  CAS  Google Scholar 

  10. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858–866.

    Article  PubMed  CAS  Google Scholar 

  11. Gu L, Okada Y, Clinton SK, et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275–281.

    Article  PubMed  CAS  Google Scholar 

  12. Gosling J, Slaymaker S, Gu L, et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773–778.

    Article  PubMed  CAS  Google Scholar 

  13. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894–897.

    Article  PubMed  CAS  Google Scholar 

  14. Dawson TC, Kuziel WA, Osahar TA, Maeda N: Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999, 143:205–211.

    Article  PubMed  CAS  Google Scholar 

  15. Ni W, Egashira K, Kitamoto S, et al.: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001, 103:2096–2101.

    PubMed  CAS  Google Scholar 

  16. Salcedo R, Ponce ML, Young HA, et al.: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34–40.

    PubMed  CAS  Google Scholar 

  17. Doyle B, Caplice N: Plaque neovascularization and anti-angiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007, 49:2073–2080.

    Article  PubMed  Google Scholar 

  18. Robinson SC, Scott KA, Balkwill FR: Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002, 32:404–412.

    Article  PubMed  CAS  Google Scholar 

  19. Schecter AD, Rollins BJ, Zhang YJ, et al.: Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997, 272:28568–28573.

    Article  PubMed  CAS  Google Scholar 

  20. Lutgens E, Faber B, Schapira K, et al.: Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 2005, 111:3443–3452.

    Article  PubMed  CAS  Google Scholar 

  21. Inoue S, Egashira K, Ni W, et al.: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 106:2700–2706.

    Article  PubMed  CAS  Google Scholar 

  22. Frangogiannis NG: The mechanistic basis of infarct healing. Antioxid Redox Signal 2006, 8:1907–1939.

    Article  PubMed  CAS  Google Scholar 

  23. Frangogiannis NG: Chemokines in ischemia and reperfusion. Thromb Haemost 2007, 97:738–747.

    PubMed  CAS  Google Scholar 

  24. Dewald O, Ren G, Duerr GD, et al.: Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004, 164:665–677.

    PubMed  CAS  Google Scholar 

  25. Birdsall HH, Green DM, Trial J, et al.: Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 1997, 95:684–692.

    PubMed  CAS  Google Scholar 

  26. Ono K, Matsumori A, Furukawa Y, et al.: Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999, 79:195–203.

    PubMed  CAS  Google Scholar 

  27. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779–17784.

    Article  PubMed  CAS  Google Scholar 

  28. Dewald O, Zymek P, Winkelmann K, et al.: CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005, 96:881–889.

    Article  PubMed  CAS  Google Scholar 

  29. Kaikita K, Hayasaki T, Okuma T, et al.: Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004, 165:439–447.

    PubMed  CAS  Google Scholar 

  30. Frangogiannis NG, Ren G, Dewald O, et al.: The critical role of endogenous thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111:2935–2942.

    Article  PubMed  CAS  Google Scholar 

  31. Deo R, Khera A, McGuire DK, et al.: Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44:1812–1818.

    Article  PubMed  CAS  Google Scholar 

  32. Hoogeveen RC, Morrison A, Boerwinkle E, et al.: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005, 183:301–307.

    Article  PubMed  CAS  Google Scholar 

  33. Lau EK, Paavola CD, Johnson Z, et al.: Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem 2004, 279:22294–22305.

    Article  PubMed  CAS  Google Scholar 

  34. Aukrust P, Halvorsen B, Yndestad A, et al.: Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008 Jul 31 [Epub ahead of print].

  35. Aukrust P, Yndestad A, Smith C, et al.: Chemokines in cardiovascular risk prediction. Thromb Haemost 2007, 97:748–754.

    PubMed  CAS  Google Scholar 

  36. Matsumori A, Furukawa Y, Hashimoto T, et al.: Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997, 29:419–423.

    Article  PubMed  CAS  Google Scholar 

  37. Nishiyama K, Ogawa H, Yasue H, et al.: Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 1998, 62:710–712.

    Article  PubMed  CAS  Google Scholar 

  38. Aukrust P, Berge RK, Ueland T, et al.: Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001, 37:485–491.

    Article  PubMed  CAS  Google Scholar 

  39. de Lemos JA, Morrow DA, Sabatine MS, et al.: Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107:690–695.

    Article  PubMed  Google Scholar 

  40. Kervinen H, Manttari M, Kaartinen M, et al.: Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol 2004, 94:993–996.

    Article  PubMed  CAS  Google Scholar 

  41. Parissis JT, Adamopoulos S, Venetsanou KF, et al.: Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 2002, 22:223–229.

    Article  PubMed  CAS  Google Scholar 

  42. de Lemos JA, Morrow DA, Blazing MA, et al.: Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007, 50:2117–2124.

    Article  PubMed  Google Scholar 

  43. Frangogiannis NG: The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 2007, 50:2125–2127.

    Article  PubMed  CAS  Google Scholar 

  44. Nathan C: Points of control in inflammation. Nature 2002, 420:846–852.

    Article  PubMed  CAS  Google Scholar 

  45. McDermott DH, Yang Q, Kathiresan S, et al.: CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005, 112:1113–1120.

    Article  PubMed  CAS  Google Scholar 

  46. Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMGCoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32:2057–2064.

    Article  PubMed  CAS  Google Scholar 

  47. Rezaie-Majd A, Maca T, Bucek RA, et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22:1194–1199.

    Article  PubMed  Google Scholar 

  48. Frangogiannis NG: Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006, 13:1877–1893.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiovascular Sciences, Baylor College of Medicine, One Baylor Plaza, BCM620, Houston, TX, 77030, USA

    Nikolaos G. Frangogiannis

Authors
  1. Carlos Gonzalez-Quesada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos G. Frangogiannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikolaos G. Frangogiannis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonzalez-Quesada, C., Frangogiannis, N.G. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 11, 131–138 (2009). https://doi.org/10.1007/s11883-009-0021-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0021-y

Keywords

Search

Navigation